

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPLUS
NEWS	23	May 27	CAPLUS super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS EXPRESS			MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004

=> le caplus uspatful europatful japio medline biosis embase
LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 16:10:45 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:10:45 ON 10 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))

L1 60 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l1 and (particle# or particulate#)

L2 29 L1 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?

L3 19 L2 AND POWDER?

=> s l3 and capsule?

L4 13 L3 AND CAPSULE?

=> s l4 and (COPD or asthma)

L5 5 L4 AND (COPD OR ASTHMA)

=> s l5 and (method or process) and (making or preparation or manufacture)

6 FILES SEARCHED...

L6 2 L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d l6 1-2 IBIB ABA

'ABA' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in .

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ABS

NO VALID FORMATS ENTERED FOR FILE 'EUROPATFULL'

In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):AB

L6 ANSWER 1 OF 2 USPATFULL on STN

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> S

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):L6 ibib ab

MISSING OPERATOR L6 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l6 1-2 IBIB AB

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP
PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP
PATENT ASSIGNEE NO: 435424
AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675 Muenchen, DE
AGENT NUMBER: 100401
OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
SOURCE: Wila-EPZ-2004-H20-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPABISCHE PATENTANMELDUNG (Internationale Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 1417975 A1 20040512
20040512
'OFFENLEGUNGS' DATE: 20040512
APPLICATION INFO.: EP 2002-747707 20020722

PRIORITY APPLN. INFO.: JP 2001-2001222148 20010723
 JP 2001-2001239895 20010807
 JP 2002-2002056449 20020301
 RELATED DOC. INFO.: WO 02-JP7385 020722 INTAKZ
 WO 2003009872 030206 INTPNR

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
 L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
 L3 19 S L2 AND POWDER?
 L4 13 S L3 AND CAPSULE?
 L5 5 S L4 AND (COPD OR ASTHMA)
 L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

=> d 15 1-5

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:757705 CAPLUS
 DN 139:265796
 TI Preparation of micronized crystalline tiotropium bromide monohydrate and formulation as inhalant to treat asthma and COPD
 IN Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef Friedrich; Walz, Michael
 PA Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310
PRAI DE 2002-10212264	A	20020320		
US 2002-413129P	P	20020924		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368320 CAPLUS
DN 136:374855
TI **Inhalant** compositions containing **tiotropium** salts and
 salmeterol salts
IN Schmelzer, Christel; Nagel, Juergen
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10056104	A1	20020523	DE 2000-10056104	20001113
	AU 2002027910	A5	20020521	AU 2002-27910	20011109
	EP 1335728	A1	20030820	EP 2001-989446	20011109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001015226	A	20031007	BR 2001-15226	20011109
	EE 200300228	A	20031015	EE 2003-228	20011109
	JP 2004513146	T2	20040430	JP 2002-540737	20011109
	US 2002193392	A1	20021219	US 2001-54567	20011113
	NO 2003002111	A	20030708	NO 2003-2111	20030512
PRAI	DE 2000-10056104	A	20001113		
	US 2000-251603P	P	20001206		
	WO 2001-EP12962	W	20011109		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:689613 CAPLUS
DN 136:390861
TI Effective delivery of **particles** with the HandiHaler dry
 powder inhalation system over a range of chronic obstructive
 pulmonary disease severity
AU Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.;
 Hochrainer, Dieter; Witek, Theodore J., Jr.
CS Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA,
 USA
SO Journal of Aerosol Medicine (2001), 14(3), 309-315
 CODEN: JAEMEP; ISSN: 0894-2684
PB Mary Ann Liebert, Inc.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 USPATFULL on STN
AN 2001:75378 USPATFULL
TI Methods and compositions for the prevention of tolerance to medications
IN Ahmed, Tahir, Coral Gables, FL, United States

PA Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S.
corporation)
PI US 6235725 B1 20010522
AI US 1999-362540 19990728 (9)
PRAI US 1998-106507P 19981030 (60)
DT Utility
FS Granted
LN.CNT 985
INCL INCLM: 514/056.000
INCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000
NCL NCLM: 514/056.000
NCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000
IC [7]
ICM: A61K031-70
EXF 514/53; 514/54; 514/56; 514/653; 514/826; 514/23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1417975 EUROPATFULL ED 20040513 EW 200420 FS OS
TIEN REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE
ACTIVE INGREDIENT.
TIDE MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND
EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
TIFR MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF
DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
IN MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1,
Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1,
Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai
3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1,
Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1,
Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai
3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai
3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP
PA ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku,
Osaka-shi, Osaka 541-8526, JP
SO Wila-EPZ-2004-H20-T1b
DS R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR;
R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR;
R AL; R LT; R LV; R MK; R RO; R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PI EP 1417975 A1 20040512
OD 20040512
AI EP 2002-747707 20020722
PRAI JP 2001-2001222148 20010723
JP 2001-2001239895 20010807
JP 2002-2002056449 20020301
RLI WO 02-JP7385 020722 INTAKZ
WO 2003009872 030206 INTPNR
IC ICM A61K045-00
ICS A61K031-559 C07D207-24 C07D207-27 C07D263-24
C07C405-00 A61P019-08 A61P019-10

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

65.21

65.42

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2004 (20040604/UP).

=> file caplus uspatful japio europaftul biosis embase medline
'EUROPAFTUL' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):europatful

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.66

66.08

FILE 'CAPLUS' ENTERED AT 16:28:44 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:28:44 ON 10 JUN 2004

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3 19 S L2 AND POWDER?
L4 13 S L3 AND CAPSULE?
L5 5 S L4 AND (COPD OR ASTHMA)
L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
ENTERED AT 16:28:44 ON 10 JUN 2004

=> s l4 1-13

MISSING OPERATOR L4 1-13

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d 14 1-13 ibib abs

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757705 CAPLUS

DOCUMENT NUMBER: 139:265796

TITLE: Preparation of micronized crystalline
tiotropium bromide monohydrate and
formulation as **inhalant** to treat asthma and
COPD

INVENTOR(S): Bender, Helmut; Graebner, Hagen; Schindler, Konrad;

Trunk, Michael Josef Friedrich; Walz, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1.

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310
PRIORITY APPLN. INFO.: DE 2002-10212264 A 20020320 US 2002-413129P P 20020924				
AB The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.0 ^{2,4}]nonane bromide, methods for the production thereof, and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect. The preparation of tiotropium bromide monohydrate microcrystals includes the solution of tiotropium bromide in water, heating, clarification with active carbon, filtration and slow crystallization followed by micronization in an air jet mill under nitrogen atmospheric and exposing the micronized crystals to water vapor. Parameters of the monocline crystals are given. Micronized crystalline tiotropium bromide monohydrate is formulated to encapsulated inhalation powder and used to treat asthma and COPD. Thus inhalation capsules contained (mg): micronized tiotropium bromide 0.0225; lactose monohydrate (200 M) 5.2025; lactose monohydrate (5 µm) 0.2750; hard gelatin capsules 49.0.				
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:889143 CAPLUS

DOCUMENT NUMBER: 137:358198

TITLE: Stable **powder** inhalation dosage formulation

INVENTOR(S): Etzler, Frank M.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482429	B1	20021119	US 2001-885349	20010620
WO 2003000240	A2	20030103	WO 2002-US18406	20020611
WO 2003000240	A3	20030306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1401409	A2	20040331	EP 2002-732063	20020611
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2001-885349 A 20010620
WO 2002-US18406 W 20020611

AB An insufflation for the administration of a drug, e.g., ipratropium bromide, albuterol sulfate or **tiotropium bromide**, into a body cavity is described where the carrier for the drug is a finely divided **powder** selected from the group consisting of myoinositol, mannitol and cellobiose. For example, the cellobiose blend with ipratropium bromide which was inhaled from **capsules** into Aerobreather at 20, 40 and 60 L/min has a lower mean **particle** size than the lactose blend, which is the opposite of the **particle** sizing results from the Aerosizer. The peaks of the distributions for the cellobiose blend were shifted to lower **particle** sizes than the lactose blend at all inhalation rates. The difference could reflect differences in adhesion strength, **particle** size distribution or size selection of retained **particles**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:695761 CAPLUS
DOCUMENT NUMBER: 137:237718
TITLE: **Inhalant** compositions containing anticholinergics and PDE IV inhibitors
INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael Paul
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069945	A2	20020912	WO 2002-EP1988	20020226
WO 2002069945	A3	20030130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10110772 A1 20020912 DE 2001-10110772 20010307
 EP 1372649 A2 20040102 EP 2002-727329 20020226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: DE 2001-10110772 A 20010307
 WO 2002-EP1988 W 20020226

OTHER SOURCE(S): MARPAT 137:237718

AB The invention relates to drug compns. based on anticholinergics and PDE IV
 inhibitors, to methods for their production, and to their use as inhalants for
 the treatment of respiratory tract diseases. Thus an inhalation
powder was composed of **capsules** that contained (μ g/
capsule): **tiotropium bromide** 21.7; AWD-12-281
 200; lactose 4778.3.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:487380 CAPLUS

DOCUMENT NUMBER: 137:68157

TITLE: **Inhalant** compositions containing
 anticholinergics and dopamine agonists

INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
 Christopher John Montague

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049624	A2	20020627	WO 2001-EP14568	20011212
WO 2002049624	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10063957	A1	20020627	DE 2000-10063957	20001220
AU 2002035767	A5	20020701	AU 2002-35767	20011212
EP 1345626	A2	20030924	EP 2001-985868	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004516264	T2	20040603	JP 2002-550966	20011212
US 2002122773	A1	20020905	US 2001-27662	20011220
PRIORITY APPLN. INFO.:			DE 2000-10063957 A	20001220
			US 2000-257221P P	20001221
			WO 2001-EP14568 W	20011212

AB The invention relates to novel pharmaceutical compns. based on
 anticholinergic agents and dopamine agonists, a method for the production of
 the compns. and the use of the same for the treatment of respiratory tract
 diseases. Thus an inhalation **powder** contained per
capsule (μ g): **tiotropium bromide** 21.7;
 viozan 270; lactose 4708.3.

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:465799 CAPLUS
 DOCUMENT NUMBER: 137:37667
 TITLE: **Inhalant** compositions containing
 anticholinergics and ciclesonide corticosteroid
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
 Christopher John Montague
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047668	A2	20020620	WO 2001-EP14579	20011212
WO 2002047668	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002031691	A5	20020624	AU 2002-31691	20011212
EP 1349549	A2	20031008	EP 2001-991827	20011212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515528	T2	20040527	JP 2002-549242	20011212
PRIORITY APPLN. INFO.:				
			DE 2000-10062712 A	20001215
			DE 2000-10054042 A	20001031
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			WO 2001-EP14579 W	20011212

AB The invention relates to novel medicament compns. based on
 anticholinesterase drugs and on ST-126, to methods for their production, and
 to their use in treating respiratory tract diseases. Thus an inhalation
 powder contained per capsule (µg): **tiotropium**
bromide x H₂O 22.5; ciclesonide 250; lactose 4727.5.

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:465798 CAPLUS
 DOCUMENT NUMBER: 137:52368
 TITLE: **Inhalant** compositions containing
 anticholinergics and ST-126 corticosteroid
 INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
 Christopher John Montague
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047667	A2	20020620	WO 2001-EP14567	20011212
WO 2002047667	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10062712 A1 20020620 DE 2000-10062712 20001215

US 2002183292 A1 20021205 US 2001-86145 20011019

AU 2002024926 A5 20020624 AU 2002-24926 20011212

PRIORITY APPLN. INFO.: DE 2000-10062712 A 20001215

DE 2000-10054042 A 20001031

US 2000-253613P P 20001128

US 2000-257220P P 20001221

WO 2001-EP14567 W 20011212

AB The invention relates to novel medicament compns. based on anticholinesterase drugs and on ST-126 corticosteroid, to methods for their production, and to their use in treating respiratory tract diseases. Thus an inhalation powder contained per capsule (µg): tiotropium bromide x H₂O 22.5; ST-126 250; lactose 4727.5.

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS

DOCUMENT NUMBER: 136:374855

TITLE: Inhalant compositions containing tiotropium salts and salmeterol salts

INVENTOR(S): Schmelzer, Christel; Nagel, Juergen

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512

PRIORITY APPLN. INFO.: DE 2000-10056104 A 20001113

US 2000-251603P P 20001206

WO 2001-EP12962 W 20011109

AB The invention relates to novel drug compns. based on tiotropium

salts and on salmeterol salts, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per **capsule** (μg): **tiotropium bromide** 10.8; salmeterol x 1/2 H₂SO₄ 27.9; Lactose 4961.3.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:353268 CAPLUS

DOCUMENT NUMBER: 136:374832

TITLE: **Inhalant** compositions containing anticholinergics and corticosteroids

INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Reichl, Richard; Schmelzer, Christel

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036106	A2	20020510	WO 2001-EP12511	20011023
WO 2002036106	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002010575	A5	20020515	AU 2002-10575	20011023
EP 1333830	A2	20030813	EP 2001-978463	20011023
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004512359	T2	20040422	JP 2002-538918	20011023
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2003181478	A1	20030925	US 2003-395777	20030324

PRIORITY APPLN. INFO.:
DE 2000-10054042 A 20001031
DE 2000-10062712 A 20001215
US 2000-253613P P 20001128
US 2000-257220P P 20001221
DE 2001-10138272 A 20010810
US 2001-314599P P 20010824
WO 2001-EP12511 W 20011023
US 2001-40196 B1 20011025

AB The invention relates to novel drug compns. based on anticholinergics and corticosteroids, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per **capsule** (μg): **tiotropium bromide** 21.7; budesonide 200; Lactose 4778.3.

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:689613 CAPLUS

DOCUMENT NUMBER: 136:390861

TITLE: Effective delivery of **particles** with the HandiHaler dry **powder** inhalation system over

a range of chronic obstructive pulmonary disease severity
 AUTHOR(S): Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.
 CORPORATE SOURCE: Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA
 SOURCE: Journal of Aerosol Medicine (2001), 14(3), 309-315
 CODEN: JAEMEP; ISSN: 0894-2684
 PUBLISHER: Mary Ann Liebert, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The HandiHaler is a dry **powder** breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of **powder** from a pierced **capsule**. We sought to document the inspiratory flow rates attained by patients inspiring through the HandiHaler with various degrees of airflow limitation. Subjects with stable chronic obstructive pulmonary disease (COPD) were the study's population. An in vitro study of fine **particle** dose was conducted using an Andersen Cascade Impactor to assess medication delivery at low inspiratory flow rates. Subsequently, an in vivo study was conducted to determine inspiratory flow rates in patients with COPD as measured through a pneumotach with a custom coupler device with and without the HandiHaler. Patients were classified into three approx. equal groups of spirometric severity ranging from mild (46-65% predicted normal forced expiratory volume in 1 s [FEV1]), to moderate (28-45%) to severe ($\leq 27\%$). The in vitro study indicated delivery of medication at flow rates as low as 20 L/min. Twenty-six men completed the in vivo study (age 66.9 ± 10.9 yr, $FEV1 = 1.02 \pm 0.451$). The median peak inspiratory flow rates attained in the mild ($n = 8$), moderate ($n = 10$), and severe ($n = 8$) categories were 45, 45.6, and 35.4 L/min resp. The min. peak inspiratory flow rates in the three groups were 28.2, 21.6 and 20.4 L/min. The HandiHaler device effectively delivers **particles** to the lung over a wide range of airflow limitation in patients with COPD.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL
 TITLE: Methods and compositions for the prevention of tolerance to medications
 INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States
 PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators.

More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL
TITLE: Supercritical fluid extraction of mould lubricant from hard shell **capsules**
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled **capsules** and dry, **powdered** pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co.,

Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun,
 Osaka 618-8585, JP;
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP
 PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome,
 Chuo-ku, Osaka-shi, Osaka 541-8526, JP
 PATENT ASSIGNEE NO: 435424
 AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675
 Muenchen, DE
 AGENT NUMBER: 100401
 OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
 SOURCE: Wila-EPZ-2004-H20-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R
 ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R
 MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R
 MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale
 Anmeldung)
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1417975	A1	20040512
		20040512
EP 2002-747707		20020722
JP 2001-2001222148		20010723
JP 2001-2001239895		20010807
JP 2002-2002056449		20020301
WO 02-JP7385	020722	INTAKZ
WO 2003009872	030206	INTPNR

 'OFFENLEGUNGS' DATE:
 APPLICATION INFO.:
 PRIORITY APPLN. INFO.:
 RELATED DOC. INFO.:

L4 ANSWER 13 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1391200 EUROPATFULL EW 200409 FS OS
 TITLE: DRUG PREPARATIONS.
 ARZNEIMITTEL.
 PREPARATIONS DE MEDICAMENTS.
 INVENTOR(S): ONUKI, Yoichi, 2-31-7, Nakadai, Narita-shi, Chiba
 286-0015, JP;
 OKADA, Minoru, 4-7-20, Kioroshihigashi, Inzai-shi, Chiba
 270-1323, JP;
 SAKAI, Hirotaka, 1-20-6, Yotsukaido, Yotsukaido-shi,
 Chiba 284-0005, JP;
 KANBE, Hideyoshi, 2-21-8, Mama, Ichikawa-shi, Chiba
 272-0826, JP;
 MIZUNO, Hiroyuki, 1-24-19, Hiyoshidai, Tomisato-machi,
 Inba-gun, Chiba 286-0201, JP;
 IMAMORI, Katsumi, 2521-86, Shimoshizushinden,
 Yotsukaido-shi, Chiba 284-0006, JP
 PATENT ASSIGNEE(S): SSP Co., Ltd., 12-4, Nihonbashi-hamacho 2-chome,
 Chuo-ku, Tokyo 103-8481, JP
 PATENT ASSIGNEE NO: 2557581
 AGENT: Hartz, Nikolai, Waechtershaeuser & Hartz,
 Patentanwaelte, Weinstrasse 8, 80333 Muenchen, DE

AGENT NUMBER: 85663
 OTHER SOURCE: MEPA2004017 EP 1391200 A1 0014
 SOURCE: Wila-EPZ-2004-H09-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1391200	A1 20040225
'OFFENLEGUNGS' DATE:		20040225
APPLICATION INFO.:	EP 2002-726486	20020524
PRIORITY APPLN. INFO.:	JP 2001-2001156853	20010525
RELATED DOC. INFO.:	WO 200JP2005041	020524 INTAKZ
	WO 2002096405	021205 INTPNR

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1	60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2	29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3	19 S L2 AND POWDER?
L4	13 S L3 AND CAPSULE?
L5	5 S L4 AND (COPD OR ASTHMA)
L6	2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
 ENTERED AT 16:28:44 ON 10 JUN 2004

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	63.51	129.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'USPATFULL' ENTERED AT 16:45:49 ON 10 JUN 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Jun 2004 (20040610/PD)
 FILE LAST UPDATED: 10 Jun 2004 (20040610/ED)
 HIGHEST GRANTED PATENT NUMBER: US6748598
 HIGHEST APPLICATION PUBLICATION NUMBER: US2004111778
 CA INDEXING IS CURRENT THROUGH 10 Jun 2004 (20040610/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Jun 2004 (20040610/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<

```

>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

```

```

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))

```

      1928 INHALANT
      236 TIOTROPIUM
      236 TIOTROPIUM
    145139 BROMIDE
      133 TIOTROPIUM BROMIDE
        (TIOTROPIUM(W) BROMIDE)
      236 TIOTROPIUM
    145139 BROMIDE
      156 MONHYDRATE
        0 TIOTROPIUM BROMIDE MONHYDRATE
          (TIOTROPIUM(W) BROMIDE(W) MONHYDRATE)

```

L7 13 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s 17 and (particle# or particulate#)

```

      552872 PARTICLE#
      156148 PARTICULATE#

```

L8 9 L7 AND (PARTICLE# OR PARTICULATE#)

=> s 12 and powder?

```

      437594 POWDER?

```

L9 3 L2 AND POWDER?

=> d 19 1-3 ibib abs

```

L9 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:132947 USPATFULL
TITLE: Medical aerosol formulations
INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
              REPUBLIC OF
              Niederlander, Carsten, Riehen, SWITZERLAND

```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA,
02205

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.

L9 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States

Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Seidleck, Brian K.
LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin,
Mary-Ellen M.

NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1487

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, **powdered** pharmaceutical
formulations are treated with supercritical fluids to remove impurities
such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-9 ibib abs

L8 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:132947 USPATFULL
TITLE: Medical aerosol formulations
INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
REPUBLIC OF
Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA,
02205
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of
stearic acid are suited for use as solid auxiliary agents for medical
suspension aerosol formulations based on hydrofluoroalkanes. They
improve, in particular, the suspension stability, the mechanical
function of the dosing valve, the dosing precision, and the chemical
stability of the active substance.

L8 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:283185 USPATFULL
TITLE: Nitrosated and nitrosylated compounds and compositions
and their use for treating respiratory disorders
INVENTOR(S): Garvey, David S., Dover, MA, UNITED STATES
Letts, L. Gordon, Dover, MA, UNITED STATES
Renfro, H. Burt, Wellesley, MA, UNITED STATES
Richardson, Stewart K., Ashford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199529	A1	20031023
APPLICATION INFO.:	US 2003-428936	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-689851, filed on 13 Oct 2000, GRANTED, Pat. No. US 6579863 Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, GRANTED, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, GRANTED, Pat. No. US 5824669 Division of Ser. No. WO 1997-US4319, filed on 19 Mar 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:176162 USPATFULL
TITLE: Medicinal aerosol formulations
INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Herzog, Kurt, Basel, SWITZERLAND
Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
Kraus, Holger, Rickenbach, SWITZERLAND
PATENT ASSIGNEE(S): Jago Research AG, MuttENZ, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585958	B1	20030701
	WO 2000006121		20000210
APPLICATION INFO.:	US 2001-744379		20010413 (9)
	WO 1999-CH337		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1998-1565	19980724
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
ASSISTANT EXAMINER:	Haghighatian, M.	
LEGAL REPRESENTATIVE:	Selitto, Behr & Kim	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	995	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pressure-liquefied propellant mixture for aerosols, comprising

dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the **particle** size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 9 USPTFULL on STN

ACCESSION NUMBER: 2003:161952 USPTFULL
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
INVENTOR(S): Garvey, David S., Waltham, MA, United States
Letts, L. Gordon, Dover, MA, United States
Renfro, H. Burt, Wellesley, MA, United States
Richardson, Stewart K., Ashford, CT, United States
PATENT ASSIGNEE(S): Nitromed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6579863	B1	20030617
APPLICATION INFO.:	US 2000-689851		20001013 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, now patented, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Badio, Barbara P.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	2028		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 9 USPTFULL on STN

ACCESSION NUMBER: 2001:75378 USPTFULL
TITLE: Methods and compositions for the prevention of tolerance to medications
INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:42141 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds, and compositions and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Dover, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfroe, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:33259 USPATFULL
 TITLE: Nitrosated and nitrosylated steroids compositions, and methods for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Waltham, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfroe, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 1998:128257 USPATFULL
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
INVENTOR(S): Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Renfro, H. Burt, Wellesley, MA, United States
Richardson, Stewart K., Ashford, CT, United States
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>
Connection closed by remote host